The Critical Medicines Act (CMA): Next steps

Europe faces persistent shortages of critical medicines, affecting patients’ access to essential treatments. COVID-19 and the geopolitical context have exposed the fragility of medicine supply chains and the EU’s reliance on limited sources of production. 

The ongoing inter-institutional negotiations should ensure the Critical Medicines Act is decisive in strengthening supply security, ensuring timely and uninterrupted access to critical medicines and reinforcing health system’s resilience.

BEUC's new two-pager summarises our main recommendations for trilogue negotiations. To find out more, read our new publication here.